Here we reported that KRAS mutations are associated with a better response to treatment with immunotherapy and worse response to platinum doublet chemotherapy as well as shorter general overall survival in Stage IV NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.